Drug: Niedrig dosiertes Naltrexon

What It Is

Low-dose naltrexone is the same opioid-blocking drug approved at 50 mg a day for opioid and alcohol dependence, taken instead at roughly a tenth of that. At the 50 mg dose the block is full and steady, the goal in dependence. At about a tenth of that dose the block is only brief and partial, thought to produce a different effect.

None of the low-dose uses is approved. No 4.5 mg naltrexone product sits on a pharmacy shelf, so a compounding pharmacy makes LDN to order on prescription. The 1 to 4.5 mg range is what defines the category.

How It Works

The low dose acts differently from the 50 mg used for addiction. Two routes are proposed, and neither has been shown directly in people. Reviews call both plausible and partly supported; the trials measure symptoms and outcomes, leaving the pathway unconfirmed.

Anatomy

1The rebound idea

Taken at night at that low dose, naltrexone briefly and partly blocks opioid receptors for a few hours. The proposed effect: the brief block leads to more endorphin and enkephalin production. That activity rises after the drug clears. This endorphin rebound is the mechanism most often offered for the pain and wellbeing effects people report. No study has measured the rise directly in people.

2The immune-cell effect

Separately, naltrexone and its relative naloxone act on a receptor called TLR4, found on microglia. Lowering TLR4 signaling on activated microglia reduces the release of inflammatory messengers. This glial, anti-inflammatory action is the leading explanation for why LDN has been studied in inflammatory conditions such as Crohn's disease, alongside pain.

3Why the low dose matters

Both proposed effects are thought to depend on the dose staying low and the block staying transient. The 50 mg dose keeps opioid receptors blocked continuously. That is why it treats dependence, and why it cannot produce the brief interruption the rebound needs. The low dose is what separates this use from the addiction use.

What Changed

Naltrexone has sold at 50 mg for years. Online, its 1-to-4.5 mg use is framed as a near-miraculous fix that drug companies deliberately buried. That story overstates an early, small body of evidence. The signals are real, but calling LDN a proven treatment reads far more into them than the trials support. Nothing was suppressed; the research is simply young and thin.

Where The Research Stands

In all three conditions the trials are small, often 10 to 40 people, with the clearest signal in fibromyalgia.

Fibromyalgia

A single-blind pilot in 10 women reported more than a 30% drop in symptoms on LDN against placebo. A later double-blind, placebo-controlled crossover trial in 31 women found a larger fall in pain on LDN than placebo, about 29% against 18%. In that trial 32% of participants met a meaningful response, against 11% on placebo. Both trials were small, both came from the same research group at one center, and both enrolled only women, leaving the effect in men untested.

Crohn's Disease

An open-label pilot in 17 adults with active Crohn's disease reported 89% improved and 67% in remission by symptom score. With everyone knowing they took the drug, there was no placebo comparison. A follow-up randomized, placebo-controlled trial in 40 adults tested a harder endpoint: the bowel lining itself. More people on LDN showed endoscopic improvement, 78% against 28% on placebo. A separate pediatric trial, blinded and placebo-controlled before an open-label phase, found the drug was tolerated in children. These small, largely single-site trials come from one group whose lead investigators hold a patent on naltrexone for inflammatory bowel disease; larger independent work has yet to confirm them.

Multiple Sclerosis

Multiple sclerosis has the weakest LDN evidence, most of it about quality of life more than the disease. An 8-week crossover trial improved mental-health quality-of-life scores but not the physical ones. A longer crossover trial found no significant effect on most quality-of-life measures. Neither was designed to show a change in disability or progression, and neither did. The benefit is modest and inconsistent, limited to some symptom and wellbeing measures, and the trials were small.

The Shape Of The Evidence

Several of the strongest trials trace to a single site or one research group. The fibromyalgia and Crohn's trials with a placebo group enrolled 31 and 40 people, and independent replication at a larger scale is mostly absent. None of that makes the signals false. The three conditions all involve inflammation, which is part of why researchers keep studying LDN.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

How it works

Proposed: the brief opioid block rebounds into more of the body's own endorphinsEmerging · mixed

In plain terms

The low dose briefly blocks opioid receptors, and the body is thought to answer by making more of its own endorphins, so there is more opioid signaling once the drug wears off. This rebound is the leading explanation for the effects people report, and it is still a hypothesis.

In detail

At roughly 1 to 4.5 mg, naltrexone briefly and partly blocks opioid receptors; the proposed response is a compensatory rise in endogenous opioid peptides (endorphins and enkephalins) after the drug clears, which is offered as the mechanism for the analgesic and wellbeing effects reported. The pathway is inferred, not directly confirmed in the human trials. The endorphin-rebound pathway is inferred from pharmacology and animal work; the clinical trials measure symptoms, not confirming a sustained rise in endogenous opioids in these patients.

The studies · 2

Younger et al., The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain · Clin Rheumatol 2014;33(4):451-459

Toljan and Vrooman, Low-Dose Naltrexone (LDN): Review of Therapeutic Utilization · Med Sci (Basel) 2018;6(4):82

Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.

Proposed: naltrexone quiets TLR4 on microglia to lower nervous-system inflammationEmerging · mixed

In plain terms

Separately from opioids, naltrexone calms a receptor called TLR4 on the immune cells of the nervous system, which lowers inflammatory signaling. This is the leading reason it has been studied in conditions driven by inflammation, not just in pain.

In detail

Naltrexone antagonizes Toll-like receptor 4 (TLR4) on microglia and other immune cells; quieting TLR4 signaling on activated microglia lowers release of pro-inflammatory mediators, which is the proposed route for effects in inflammation-driven conditions and is distinct from classic opioid-receptor action. The glial anti-inflammatory effect is established in laboratory models; its contribution to the clinical results in people has not been measured directly in the trials.

The study · 1

Younger et al., The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain · Clin Rheumatol 2014;33(4):451-459

Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.

Pain

Fibromyalgia pain fell about 29% vs 18% on placebo in a 31-woman RCTEmerging

In plain terms

In a randomized trial of 31 women, the low dose reduced pain more than placebo, by about 29% against 18%. A consistent but small signal in the best-studied use.

In detail

In a double-blind, placebo-controlled, counterbalanced crossover trial of 31 women with fibromyalgia, low-dose naltrexone reduced daily pain more than placebo (about 29% versus 18%, P=0.016), and 32% met a clinically meaningful response against 11% on placebo. 31 participants from a single center and one research group, without larger independent replication.

Who this may not transfer to:Conducted entirely in women; the effect in men with fibromyalgia was not tested, so it is unknown, not assumed to transfer.

The study · 1

Younger et al., Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial · Arthritis Rheum 2013;65(2):529-538

Fibromyalgia symptoms fell more than 30% over placebo in a 10-woman pilotPreliminary

In plain terms

In a small early study of 10 women, the low dose cut fibromyalgia symptoms by more than 30% compared with placebo. It is an encouraging first signal from a very small, single-center study.

In detail

In a single-blind, placebo-controlled crossover pilot of 10 women with fibromyalgia, low-dose naltrexone (4.5 mg) reduced self-reported symptoms by more than 30% relative to placebo. Ten participants, single-blind, single site, one research group; a pilot that motivates a larger trial, not establishing the effect.

Who this may not transfer to:Studied only in women, which fits a condition diagnosed far more often in women, but the effect in men was not tested and is unknown, not assumed similar.

The study · 1

Younger and Mackey, Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study · Pain Med 2009;10(4):663-672

Digestion

Bowel-lining healing in 78% vs 28% on placebo in a 40-adult Crohn's RCTEmerging

In plain terms

In a randomized trial of 40 adults, more people on the low dose showed healing of the bowel lining seen on endoscopy than on placebo, 78% against 28%. Healing seen on camera is a stronger sign than feeling better.

In detail

In a randomized, placebo-controlled trial of 40 adults with active Crohn's disease, more participants on low-dose naltrexone showed endoscopic improvement of the bowel lining than on placebo (78% versus 28%, p=0.008), a mucosal endpoint harder than symptom scores alone. The primary clinical endpoint, a 70-point drop in the disease-activity index, was met by 88% on the drug against 40% on placebo. 40 participants at a single site from one research group, whose lead investigators hold a patent on naltrexone for inflammatory bowel disease; a promising mucosal result that awaits larger independent confirmation.

The studies · 2

Smith et al., Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial · Dig Dis Sci 2011;56(7):2088-2097

Smith et al., Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study · J Clin Gastroenterol 2013;47(4):339-345

Crohn's response in 89% and remission in 67% of a 17-adult open-label pilotPreliminary

In plain terms

In an early open-label study of 17 adults with active Crohn's disease, 89% improved and 67% reached remission by symptom score. Open-label means everyone knew they were taking the drug, so the placebo effect is not controlled.

In detail

In an open-label pilot of 17 adults with active Crohn's disease, 89% responded to low-dose naltrexone and 67% reached remission by the Crohn's Disease Activity Index over twelve weeks. With no control group, expectation and natural fluctuation are not separated out. 17 participants, open-label with no placebo control, so improvement cannot be separated from expectation or natural fluctuation.

The study · 1

Smith et al., Low-dose naltrexone therapy improves active Crohn's disease · Am J Gastroenterol 2007;102(4):820-828

Autoimmune Neuro

Mixed quality-of-life results in MS, with no change in disabilityPreliminary

In plain terms

In multiple sclerosis the results are mixed and mostly about wellbeing, not the disease itself. One short trial improved some mental-health quality-of-life scores; a longer one found little effect. Neither changed disability or the course of the disease.

In detail

Randomized crossover trials in multiple sclerosis report mixed results: an eight-week trial improved mental-health quality-of-life scores but not physical ones, while a longer crossover trial found no significant effect on most quality-of-life measures. Neither was designed to alter, nor showed a change in, disability or disease progression. Small crossover trials with inconsistent findings, limited to quality-of-life measures, not disability progression, so this is a modest and uncertain symptom signal, not a disease-modifying effect.

The studies · 2

Cree et al., Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis · Ann Neurol 2010;68(2):145-150

Sharafaddinzadeh et al., The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial · Mult Scler 2010;16(8):964-969

Go Deeper

At its 1-to-4.5 mg dose, LDN belongs with other old, inexpensive drugs studied for unapproved uses, where interest has outpaced large trials.

• Fibromyalgia: the condition with the clearest LDN signal.
• Metformin: an old, inexpensive drug studied well beyond its approved use.
• Peptides: a neighboring area of early, small-trial evidence.
• Ivermectin: another repurposed drug where claims ran ahead of the data.

The Chinese Medicine View

No classical Chinese source lists LDN, a modern drug taken at a few milligrams. It has no assigned channel, temperature or flavor, and no traditional formula contains it. No herb reproduces what the drug does. TCM practitioners do still recognize the conditions it is studied for. Fibromyalgia, with its shifting widespread pain and fatigue, is read through Liver Qi stagnation, Blood stasis and underlying deficiency. The chronic bowel inflammation of Crohn's disease is read through Spleen and Stomach weakness with Damp-Heat. A practitioner treats the whole diagnosed pattern, and would first assess whether a depleted patient has the reserves to respond. Chinese medicine does not explain or endorse LDN.

Cautions

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

Generally well tolerated at low dose, but it blocks opioid painkillers

Across the trials, low-dose naltrexone is generally well tolerated, with vivid dreams and sleep disturbance the most commonly reported effects and few serious adverse events. It is contraindicated with opioid medication, because it blocks opioid receptors and can precipitate withdrawal, and it carries caution in significant liver disease. Tolerability data come from small trials of limited duration; the compounded, off-label supply falls outside the checks that apply to an approved product.Toljan and Vrooman, Low-Dose Naltrexone (LDN): Review of Therapeutic Utilization

It cannot be combined with opioid medication

Naltrexone blocks opioid receptors, so taking it with opioid pain medicine can cancel the pain relief and can trigger withdrawal in someone dependent on opioids. Anyone taking opioids, or facing surgery where opioids may be needed, must clear LDN with a prescriber first.

It is compounded, and preparations differ

No approved low-dose product exists, so a compounding pharmacy prepares each batch, and preparations differ between pharmacies. A compounded drug sits outside the checks that cover approved medicines. A prescriber can pick a reliable pharmacy and follow up on how it is tolerated.

Vivid dreams and sleep effects

The most commonly reported side effect is vivid or unusual dreams and disturbed sleep, especially in the first weeks and when the drug is taken at night. For most people in the trials this was mild and settled with time.

It is not a proven treatment for these conditions

LDN should not replace an established treatment for a serious condition such as multiple sclerosis or active Crohn's disease. Any trial of it belongs alongside that care.

Liver and other medicines

The liver processes naltrexone, so it carries cautions in significant liver disease. Drug interactions, opioids above all, need a prescriber who has the full medication list.

Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.

Common Questions

Is low-dose naltrexone the same drug used for addiction?

Yes. It is the same molecule. At 50 mg it treats opioid and alcohol dependence with a steady, full receptor block. At the low dose that block is brief and partial, and every low-dose use is off-label.

Is low-dose naltrexone safe?

At that low dose, LDN was generally well tolerated in the trials, with few serious problems reported.

The main limit is that it must never be combined with opioid pain medicine.

Why isn't it approved if the results look encouraging?

Naltrexone has been prescribed at 50 mg for many years and is cheap and off-patent, so a company has little commercial reason to fund the large trials that approval needs. The evidence so far, though encouraging in fibromyalgia and Crohn's disease, is not yet the large, multi-center kind approval requires.